Company Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
3.1 ^USD	+6.22%		-15.76%	-3.16%

Mar. 26	Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patientsâ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Number of employees: 7

Managers	Title	Age	Since
Jeffrey Gudin FOU	Founder	58	16-12-31
Gerald Bruce CEO	Chief Executive Officer	68	17-07-31
Vinay Shah DFI	Director of Finance/CFO	62	23-06-19
Sheila A. Mathias CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Gerald Bruce CEO	Chief Executive Officer	68	17-07-31
Jeffrey Gudin FOU	Founder	58	16-12-31
Barbara A. Ruskin BRD	Director/Board Member	-	23-03-23
Eric Floyd CHM	Chairman	62	16-12-31
Jerrold Sendrow BRD	Director/Board Member	79	16-12-31
Vanila Singh BRD	Director/Board Member	53	20-05-31
Thani Jambulingam BRD	Director/Board Member	60	16-12-31
Michael Dubin BRD	Director/Board Member	68	21-07-25

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,171,233	869,973 ( 74.28 %)	0	74.28 %

Name	Equities	%	Valuation
Anthony Mack 25.47 %	298,298	25.47 %	1 M $
PNC Financial Services Group, Inc. (13F Subfiler) 0.8613 %	10,088	0.8613 %	42 985 $
Vanguard Group, Inc. (Subfiler) 0.5660 %	6,629	0.5660 %	28 246 $
Geode Capital Management LLC 0.5458 %	6,393	0.5458 %	27 241 $
Sheets Smith Wealth Management 0.4269 %	5,000	0.4269 %	21 305 $
Renaissance Technologies LLC 0.2604 %	3,050	0.2604 %	12 996 $
G1 Execution Services LLC 0.1514 %	1,773	0.1514 %	7 555 $
Northern Trust Investments, Inc.(Investment Management) 0.1299 %	1,522	0.1299 %	6 485 $
Two Sigma Securities LLC 0.0999 %	1,170	0.0999 %	4 985 $
Jerrold Sendrow 0.0768 %	900	0.0768 %	3 835 $

Virpax Pharmaceuticals, Inc.

1055 Westlakes Drive Suite 300

19312, Berwyn

http://www.virpaxpharma.com

address Virpax Pharmaceuticals, Inc.(VRPX)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.1 USD

Average target price

20 USD

Spread / Average Target

+545.16%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRPAX PHARMACEUTICALS, INC.	-3.16%	3.63M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research